NCT05683834 2026-04-22
Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
Clinical Trials
10 trialsNCT02580539 2025-05-14
EBV-TCL-01
Maisonneuve-Rosemont Hospital
Phase 1/2 Completed
NCT00478465 2022-05-27
Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)
Stanford University
Phase 1/2 Completed
NCT02496676 2022-03-02
Magnesium Supplementation in People With XMEN Syndrome
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02227641 2020-12-14
Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation
University of Erlangen-Nürnberg Medical School
Phase 1/2 Completed
NCT02000817 2019-06-24
Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients
GlaxoSmithKline
Phase 1/2 Completed
NCT01570283 2019-05-30
ARMS
AlloVir
Phase 1/2 Completed
NCT00575185 2017-03-22
Mono6
University of Minnesota
Phase 1/2 Completed
NCT00711035 2016-04-26
CHALLAH
Baylor College of Medicine
Phase 1/2 Completed
NCT00274404 2011-10-27
Controlled Trial of Valacyclovir in Infectious Mononucleosis
University of Minnesota
Phase 1/2 Completed